Screener
BridgeBio Pharma BBIO Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
FAQ
- What is BridgeBio Pharma's operating lease liabilities (current)?
- BridgeBio Pharma (BBIO) reported operating lease liabilities (current) of $3.32M in Q2 2026.
- How has BridgeBio Pharma's operating lease liabilities (current) changed year-over-year?
- BridgeBio Pharma's operating lease liabilities (current) decreased by 30.7% year-over-year, from $4.78M to $3.32M.
- What is the long-term trend for BridgeBio Pharma's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease liabilities (current) has grown at a 10.3% compound annual growth rate (CAGR), from $3.8M to $6.19M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about BridgeBio Pharma's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude